755026-96-1

Basic information

• Product Name: 2-(3-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• Synonyms: 2-(3-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;3-Methoxy-4-nitrophenylboronic acid, pinacol ester
• CAS NO: 755026-96-1
• Molecular Formula: C₁₃H₁₈BNO₅
• Molecular Weight: 279.09672
• Mol File: 755026-96-1.mol

Chemical Properties

• Boiling Point: 406.8±35.0 °C(Predicted)
• Appearance: /
• Density: 1.16±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 2-(3-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(755026-96-1)
• EPA Substance Registry System: 2-(3-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(755026-96-1)

Safety Data

• Hazardous Substances Data: 755026-96-1(Hazardous Substances Data)

Usage

Uses

Used in Synthetic Chemistry:
2-(3-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is used as a key component in various chemical reactions for the synthesis of new materials and compounds. Its unique structure and reactivity make it a valuable asset in the development of innovative products and processes in the chemical industry.
Used in Material Development:
In the field of material science, 2-(3-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is employed as a crucial element in the synthesis of advanced materials with specific properties. Its involvement in chemical reactions can lead to the creation of materials with improved performance characteristics, such as enhanced stability, reactivity, or selectivity.
Used in Pharmaceutical Industry:
2-(3-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is utilized as an intermediate or building block in the synthesis of pharmaceutical compounds. Its unique properties and reactivity can contribute to the development of new drugs with improved therapeutic effects and reduced side effects.
Used in Research and Development:
In academic and industrial research settings, 2-(3-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane is employed as a versatile compound for exploring new chemical reactions and mechanisms. Its unique structure and reactivity provide opportunities for scientists to investigate novel pathways and develop innovative synthetic strategies.

Upstream product

• 103966-66-1 4-bromo-2-methoxy-1-nitro-benzene 
• 73183-34-3 bis(pinacol)diborane 
• 6627-53-8 1-chloro-3-methoxy-4-nitrobenzene 

Downstream Products

• 755027-09-9 methyl [3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-8-yl]acetate 
• 755030-88-7 methyl 2-[3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-8-yl]-2-methylpropanoate 
• 755029-56-2 methyl 3-[3-(3-methoxy-4-nitrophenyl)-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-8-yl]propanoate 
• 755027-14-6 3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 
• 949570-64-3 3-(3-methoxy-4-nitrophenyl)-6-((2-(trimethylsilyl)ethoxy)methoxy)-5H-dibenzo[b,e][1,4]diazepin-11(10H)-one 
• 755027-95-3 8-amino-3-(3-methoxy-4-nitrophenyl)-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 
• 755034-28-7 8-methoxy-3-(3-methoxy-4-nitrophenyl)-7-{[2-(trimethylsilyl)ethoxy]methoxy}-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one 
• 1578245-91-6 2-methoxy-4-(1-methyl-1H-imidazol-5-yl)aniline 

Relevant articles and documents

HETEROARYL DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a heteroaryl derivative and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient, and a compound according to an aspect of the present invention, a stereoisomer

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 1 PROTEINS

The present invention relates to compounds comprising an interleukin-1 receptor-associated kinase 1 (IRAK1) protein binding moiety and a Von Hippel-Lindau (VHL) E3 ubiquitin ligase binding moiety, and associated methods of use. The compounds are useful as modulators of targeted ubiquitination, especially with respect to IRAK1, which is degraded by the compounds according to the invention.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

TAU IMAGING PROBE

An object of the present invention is to provide a probe for imaging a β-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity. According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R1, R2, R3, R4, R5, R6, Ra and Rb are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.

Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1, 4]diazepin-11-one-based potent and selective Chk-1 inhibitors

A novel series of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-ones have been synthesized as potent and selective checkpoint kinase 1 (Chk1) inhibitors via structure-based design. Aided by protein X-ray crystallography, medicinal chemistry efforts led to the

HETEROCYCLIC KINASE INHIBITORS

Compounds having the formula (I) are useful for inhibiting protein kinases. Also disclosed are methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.